Culprit Tumor as an Unexpected Extraosseous MDP Activity on Bone Scintigraphy in a Patient With Tumor-Induced Osteomalacia.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
18
9
2020
Statut:
ppublish
Résumé
A 39-year-old man with bone pain underwent Tc-MDP bone scan to assess skeletal lesions, which demonstrated multiple fractures and a focus of subtle extraosseous activity in the left thigh. A Tc-hynic-octreotide imaging was performed due to the suspected diagnosis of tumor-induced osteomalacia, which revealed a hypermetabolic subcutaneous nodule in the left thigh, which exactly corresponded to the same site of MDP activity. Biopsy confirmed the subcutaneous nodule as the culprit tumor of tumor-induced osteomalacia. Bone scan, as a conventional imaging, provided useful information for detecting culprit tumor as shown in our case.
Identifiants
pubmed: 32366790
doi: 10.1097/RLU.0000000000003042
pii: 00003072-202006000-00024
doi:
Substances chimiques
Technetium Tc 99m Medronate
X89XV46R07
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
492-494Références
Arai R, Onodera T, Terkawi MA, et al. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia. BMC Musculoskelet Disord. 2017;18:79.
Jiang Y, Xia WB, Xing XP, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res. 2012;27:1967–1975.
Chong WH, Molinolo AA, Chen CC, et al. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;18:R53–R77.
Tirosh A, Kebebew E. The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Future Oncol. 2018;14:111–122.
Jing H, Li F, Wang L, et al. Comparison of the 68Ga-DOTATATA PET/CT, FDG PET/CT, and MIBG SPECT/CT in the evaluation of suspected primary pheochromocytomas and paragangliomas. Clin Nucl Med. 2017;42:525–529.
Gofrit ON, Frank S, Meirovitz A, et al. PET/CT with 68Ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate Cancer. Clin Nucl Med. 2017;42:1–6.
Herrmann K, Czernin J, Wolin EM, et al. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician’s perspective. J Nucl Med. 2015;56:70–75.
Moradi F, Jamali M, Barkhodari A, et al. Spectrum of 68Ga-DOTA TATE uptake in patients with neuroendocrine Tumors. Clin Nucl Med. 2016;41:e281–e287.
Jing H, Li F, Zhuang H, et al. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan. Eur J Radiol. 2013;82:2028–2034.
Zhang J, Zhu Z, Zhong D, et al. 68Ga DOTATATE PET/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia. Clin Nucl Med. 2015;40:642–646.
El-Maouche D, Sadowski SM, Papadakis GZ, et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2016;101:3575–3581.
Jing H, Li F, Zhong D, et al. 99mTc-HYNIC-TOC (99mTc-hydrazinonicotinyl-Tyr3-octreotide) scintigraphy identifying two separate causative tumors in a patient with tumor-induced osteomalacia (TIO). Clin Nucl Med. 2013;38:664–667.
Palot Manzil FF, Bhambhvani PG, O’Malley JP. Evaluation of tumor-induced osteomalacia with 111In-pentetreotide scintigraphy. J Nucl Med Technol. 2013;41:299–301.
Wang L, Zhang S, Jing H, et al. The findings on bone scintigraphy in patients with suspected tumor-induced osteomalacia should not be overlooked. Clin Nucl Med. 2018;43:239–245.
Garcia CA, Spencer RP. Bone and in-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med. 2002;27:582–583.
Casari S, Rossi V, Varenna M, et al. A case of oncogenic osteomalacia detected by 111In-pentetreotide total body scan. Clin Exp Rheumatol. 2003;21:493–496.